Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enrupatinib - Elixiron Immunotherapeutics

Next Previous
Drug Profile

Enrupatinib - Elixiron Immunotherapeutics

Alternative Names: EI-1071

Latest Information Update: 26 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elixiron Immunotherapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Macrophage colony-stimulating factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Giant cell tumour of tendon sheath
  • No development reported Breast cancer; Colorectal cancer

Most Recent Events

  • 20 Dec 2024 Phase-II clinical trials in Alzheimer's disease (Treatment-experienced) in Taiwan (PO) (NCT06745583)
  • 28 Jul 2024 Adverse event data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
  • 28 Jul 2024 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top